Chronic heart failure is characterised by varying degrees of symptoms and high mortality mainly from progressive myocardial failure and sudden death. Increased understanding of pathophysiological mechanisms has shown that heart failure is progressive and characterised by myocardial dysfunction and activation of complex adaptive and maladaptive processes. Moreover, a number of large clinical trials have shown that the progressive nature of and high mortality from the disorder may be affected by pharmacological interventions.
The initial event in the clinical pathophysiology of heart failure is myocardial damage, which may be caused by many different mechanisms such as toxins, infections, and prolonged volume or pressure overload.' In Western societies the initial injury is most often an acute myocardial infarction, though the cause often remains unknown, as in idiopathic dilated cardiomyopathy. Clinical heart failure may develop immediately after the myocardial injury or after a period of asymptomatic left ventricular dysfunction. The pathophysiological events which follow an acute myocardial injury and ultimately lead to progressive heart failure are not exactly understood, although our knowledge of the complicated mechanisms involved in the development of left ventricular dilatation, hypertrophy, and dysfunction has recently increased.2 Activation of different neurohormonal systems as well as autocrine and paracrine mechanisms has an essential role in this process.
Pharmacological treatment of chronic heart failure has traditionally been aimed at the underlying cardiac disease and at reducing symptoms such as dyspnoea and fluid retention. More recently, treatment has been targeted increasingly at delaying the progression of the disorder and at reducing mortality. Treatment with angiotensin converting enzyme (ACE) inhibitors can positively influence prognosis. Moreover, 1 adrenergic blockers can reduce mortality in patients with heart failure after myocardial infarction,6 and they seem to delay the progression of the disorder among patients with idiopathic dilated cardiomyopathy.7 ACE inhibitors have multiple mechanisms of action, which involve both haemodynamic and neurohormonal factors as well as autocrine and paracrine mechanisms. In this article we will review the importance of neurohormonal mechanisms for the efficacy of ACE inhibitors in the treatment of asymptomatic left ventricular dysfunction and chronic heart failure. Although doctors focus on treatment of patients with systolic dysfunction of the left ventricle, it is important to remember that, in some cases of heart failure, alterations in myocardial relaxation (diastolic dysfunction) may predominate.8
Although the initial event in the development of left ventricular dysfunction is structural damage to the myocardium, heart failure is not merely a disease of the heart. Patients with left ventricular dysfunction frequently have no symptoms of heart failure, probably because compensatory mechanisms enable maintenance of cardiac output and peripheral perfusion. These adaptive responses are the result of a complex interplay between myocardial, haemodynamic, and neurohormonal mechanisms which are activated almost immediately after the myocardial injury. Compensatory mechanisms may, however, become exhausted, and many patients ultimately develop symptoms of heart failure. At this stage, activation of the sympathetic nervous system and the renin-angiotensin system seems to be maladaptive and may cause further harm to the myocardium, leading to progression of the disorder.9 10 Furthermore, baroreflex responses are not able to limit the magnitude of activation of the vasoconstrictor hormones as baroreceptor function may be impaired." 12 Thus, sustained neurohormonal activation is partly maintained by altered baroreceptor function, which may reduce inhibitory signals to the vasomotor centre and thereby diminish the inhibition of sympathetic outflow.
The time course of neurohormonal acti- 41 and 180 days because the study was stopped prematurely. Patients were eligible for inclusion if they presented within 24 hours after the onset of chest pain that was likely to be due to an acute myocardial infarction and showed either electrocardiographic changes or raised plasma concentrations of enzymes indicating myocardial damage. Mortality in the groups given enalapril and placebo was respectively 7.2% and 6-3% after the first month and 11*0% and 10-2% after six months. The differences between the groups were not significant. Heart failure was associated with the index infarction among 1109 patients (18%). There was no difference in survival between the two treatment groups in the subgroup of patients with heart failure.
In the SAVE trial 2231 patients with ejection fractions of 40% or less but without overt heart failure or symptoms of myocardial ischaemia were randomly assigned to treatment with captopril or placebo within 3 to 16 days after myocardial infarction.67 At the time of randomisation 35% of the patients were taking diuretics, but patients whose symptoms of heart failure were not readily controlled were excluded from the trial. Thus, the SAVE trial studied a mixed population of patients with mild symptomatic heart failure and asymptomatic left ventricular dysfunction. The patients were followed up for an average of 42 months. Mortality from all causes was 20% in the group given captopril and 25% in the group given placebo. This corresponds to a risk reduction of 19% (P = 0 0 19). The proportion of patients who needed to be admitted to hospital for congestive heart failure was higher in the placebo group (17%) than in the captopril group (14%) (risk reduction 22%; P = 0.019). Furthermore, the risk of developing a fatal or non-fatal myocardial infarction was reduced by 25% (P = 0-0 15) in the captopril group compared with the placebo group. In the AIRE study 2006 patients with clinical evidence of heart failure at any time after the index infarction were randomly allocated to treatment with ramipril or placebo on the third to tenth day after the onset of infarction.65 Clinical evidence of heart failure was defined as at least one of the following: signs of left ventricular failure in a chest radiograph, bilateral auscultatory crackles extending at least one third of the way up the lung fields in the absence of chronic pulmonary disease, or auscultatory evidence of a third heart sound with persistent tachycardia. The average time of follow up was 15 months with a minimum of six months. Mortality from all causes at the end of the study was 17% in the ramipril group and 23% in the placebo group (risk reduction 27%; P = 0 002).
In the large ISIS-4 study 58 000 patients were randomly assigned treatment with captopril or placebo within 24 hours after the onset of a suspected or definite acute myocardial infarction. Mortality after five weeks was compared between the treatment groups. When data from 54 824 patients had been analysed, mortality was 7.33% in the placebo group and 6.87% in the captopril group (relative risk reduction 6%). Although the absolute risk reduction was small (<05%), it was significant (P = 0 04). Fourteen per cent of the patients had heart failure at the time of inclusion.66 In the GISSI-3 study 18 of acute myocardial infarction. After six weeks of treatment, mortality was 7 10% among controls and 6-3% among patients receiving lisinopril, a relative risk reduction of 1 1%, which was significant (P = 0-03).67 There are some major differences between these five large clinical trials: different patient populations were selected, the duration of treatment and follow up was different, the time at which treatment was started varied, and different ACE inhibitors were used. These differences must be considered when the results of these trials are compared. Given that only patients with sustained neurohormonal activation will benefit from treatment with ACE inhibitors after myocardial infarction, however, some of the results may be explained. As previously mentioned, patients with sustained neurohormonal activation are those with clinical symptoms of heart failure and those with reduced ejection fractions or extensive myocardial damage, even in the absence of overt heart failure. These patients benefited from treatment in the AIRE and SAVE trials. Only a fraction of the patients included in the CONSENSUS II trial, however, can be presumed to have had prolonged neurohormonal activation, and the study would not have had statistical power to detect possible differences in survival, even if such differences existed in this subgroup. In the ISIS-4 and GISSI-3 studies a small difference in mortality was observed. This effect may have been confined to patients with clinical characteristics similar to those of patients in the AIRE trial. Although this may be an attractive hypothesis, it is not supported by recent data from the SAVE trial showing that the clinical benefits produced by captopril were not limited to the group with neurohormonal activation at inclusion into the study.22 Thus, the importance of neurohormonal activation for the effects of ACE inhibition after acute myocardial infarction is still uncertain.
Trials with ACE inhibitors in patients with chronic heart failure The CONSENSUS trial showed convincingly that survival may be improved by treatment with an ACE inhibitor in patients with severe heart failure.3 Blood samples for hormone analyses were drawn at baseline from 239 patients who were randomly allocated to treatment with enalapril or placebo in this trial.32 A significant reduction in mortality in the group of patients treated with enalapril, compared with patients receiving placebo, was consistently found among patients with plasma concentrations of noradrenaline, adrenaline, angiotensin II, aldosterone, or atrial natriuretic peptide above the median. No significant differences in survival between the treatment groups were found among patients with hormone concentrations below the median.
However, the few patients studied demands caution in interpretation.
In the V-HeFT II trial 804 men receiving digoxin and diuretics for heart failure were randomly allocated to treatment with enalapril or a combination of hydralazine and isosorbide dinitrate.4 Mortality after two years was significantly lower in the enalapril arm than in the hydralazine-isosorbide dinitrate arm. Plasma noradrenaline concentration and renin activity at baseline were analysed in 743 and 737 patients respectively. 38 The survival benefit of enalapril compared with hydralazine-isosorbide dinitrate was most evident in patients with a plasma noradrenaline value higher than 900 pg/ml and among patients with a plasma renin activity higher than 4-4 ng/(l s).
Together the results of these studies indicate that neurohormonal activation is a major determinant of the clinical efficacy of treatment with ACE inhibitors in chronic heart failure. Furthermore, the importance of neurohormonal activation in the progression of this disorder and its high mortality is underscored.
Neurohormonal activation: therapeutic target in patients with left ventricular dysfunction or chronic heart failure In patients with left ventricular dysfunction but no overt heart failure the actions of the vasoconstrictor systems seem to be adequately counterbalanced by endogenous vasodilator factors. Increased secretion of atrial and brain natriuretic peptides from the atria and ventricles may antagonise many of the effects of the vasoconstrictor systems.6869 Although these patients are asymptomatic and haemodynamically stable, some neurohormonal mechanisms may have already become maladaptive. High circulating concentrations of noradrenaline and angiotensin II may cause necrosis of myocardial cells, and angiotensin II may induce hypertrophy in cardiac myocytes.7072 In symptomatic heart failure the activation of counter-regulatory vasodilator systems seems to be overwhelmed by activation of vasoconstrictor mechanisms such as the renin-angiotensin system and the sympathetic nervous system. Release of endothelium derived relaxing factor may be attenuated in patients with heart failure.73 In addition, the haemodynamic and hormonal response to atrial natriuretic peptide may become blunted.7F76 The haemodynamic consequences of this shift of balance is increased peripheral resistance and sodium retention, which will add further to the haemodynamic burden of the heart.
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